9-130714339-A-G
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2
The NM_007313.3(ABL1):āc.20A>Gā(p.Lys7Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000011 in 1,458,634 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Consequence
NM_007313.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -4 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.0000200 AC: 5AN: 249498Hom.: 0 AF XY: 0.0000371 AC XY: 5AN XY: 134900
GnomAD4 exome AF: 0.0000110 AC: 16AN: 1458634Hom.: 0 Cov.: 31 AF XY: 0.00000965 AC XY: 7AN XY: 725314
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
The c.20A>G (p.K7R) alteration is located in exon 1 (coding exon 1) of the ABL1 gene. This alteration results from a A to G substitution at nucleotide position 20, causing the lysine (K) at amino acid position 7 to be replaced by an arginine (R). The p.K7R alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
not provided Uncertain:1
This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 7 of the ABL1 protein (p.Lys7Arg). This variant is present in population databases (rs375730000, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with ABL1-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ABL1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at